PTAB Tracker

Abatacept (Orencia)+

U.S. Patent 8,476,239
Patent Owner: Bristol-Myers Squibb
Title: Stable Protein Formulations

IPR2015-01537, filed by Momenta

Adalimumab (Humira)+

U.S. Patent 8,889,135
Patent Owner: Abbvie Biotechnology, Ltd.
Title: Methods of Administering anti-TNFa-antibodies

IPR2016-00408, filed by Boehringer Ingelheim

IPR2016-00409, filed by Boehringer Ingelheim

IPR2016-00172, filed Coherus BioSciences, Inc.

U.S. Patent 9,017,680
Patent Owner: Abbvie Biotechnology, Ltd.
Title: Methods of Administering anti-TNFa antibodies

IPR2016-00188, filed by Coherus BioSciences

U.S. Patent 9,073,987
Patent Owner: AbbVie Biotechnology, Ltd.
Title: Methods of Administering anti-TNFa antibodies

IPR2016-00189, filed by Coherus BioSciences

U.S. Patent 9,085,619
Patent Owner:  Abbvie Biotechnology
Title: Anti-TNF Antibody Formulations

IPR2017-01009, filed by Coherus BioSciences, Inc.

IPR2017-01008, filed by Coherus

IPR2017-00822, filed by Coherus BioSciences, Inc.

IPR2017-00823, filed by Coherus BioSciences, Inc.

IPR2017-00826, filed by Coherus BioSciences, Inc.

  • Filing date: January 31, 2017
  • Status: Unopposed motion to dismiss petitions without prejudice filed by petitioner on April 7, 2017 and granted on April 11, 2017
  • Petition

IPR2017-00827, filed by Coherus BioSciences, Inc.

  • Filing date: January 31, 2017
  • Status: Unopposed motion to dismiss petitions without prejudice filed by petitioner on April 7, 2017 and granted on April 11, 2017
  • Petition

U.S. Patent 8,802,100
Patent Owner:  AbbVie  Biotechnology
Title:  Formulation of human antibodies for treating TNF-alpha associated disorders

IPR2017-01823, filed by Sandoz

U.S. Patent 9,512,216
Patent Owner:  AbbVie Biotechnology
Title:  Use of TNFa Inhibitor

IPR2017-01824, filed by Sandoz

IPR2018-00002, filed by Sandoz

U.S. Patent 8,911,737
Patent Owner: AbbVie Biotechnology
Title: Methods of administering anti-TNFa antibodies

IPR2017-01987, filed by Sandoz

IPR2017-01988, filed by Sandoz

U.S. Patent 9,090,689
Patent Owner: AbbVie Biotechnology
Title: Use of TNFa inhibitor for treatment of psoriasis

IPR2017-02105, filed by Sandoz

U.S. Patent 9,067,992
Patent Owner:  AbbVie Biotechnology
Title:  Use of TNFa inhibitor for treatment of psoriatic arthritis

IPR2017-02106, filed by Sandoz

U.S. Patent 8,916,157
Patent Owner:  AbbVie Biotechnology
Title:  Formulation of human antibodies for treating TNF-a associated disorders

IPR2015-01514, filed by Amgen

U.S. Patent 8,916,158
Patent Owner: AbbVie Biotechnology
Title: Formulation of Human Antibodies for Treating RNF-a Associated Disorders

IPR2015-01517, filed by Amgen

U.S. Patent 9,114,166
Patent Owner: AbbVie Biotechnology
Title:  Formulation of Human Antibodies for Treating TNF-a Associated Disorders

IPR2016-01018, filed by Coherus

U.S. Patent 9,187,559
Patent Owner: Abbvie Biotechnology
Title:  Multiple-Variable Dose Regimen for Treating Idiopathic Inflammatory Bowel Disease

IPR2018-00156, filed by Sandoz

Bevacizumab (Avastin)+

U.S. Patent 7,622,115
Patent Owner:  Genentech
Title: Treatment with anti-VEGF antibodies

IPR2016-01771, filed by Hospira

U.S. Patent 9,795,672
Patent Owner: Genentech
Title: Treatment with Anti-VEGF Antibodies

IPR2018-00373, filed by Pfizer

Dupilumab (Dupixent)+

U.S. Patent 8,679,487
Patent Owner: Immunex Corp.
Title: Anti-interleukin-4 receptor antibodies

IPR2017-01879, filed by Sanofi-Aventis

IPR2017-01129, filed by Sanofi Aventis

IPR2017-01884, filed by Sanofi Aventis

Eculizumab (Soliris®)+

U.S Patent 9,725,504
Patent Owner: Alexion Pharmaceuticals Inc.
Title: Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement

IPR2019-00739, filed by Amgen

  • Filing date: February 28, 2019
  • Status: Petition pending.
  • Petition

U.S. Patent No. 9,718,880
Patent Owner: Alexion Pharmaceuticals Inc
Title: Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement

IPR2019-00740, filed by Amgen

  • Filing date: February 28, 2019
  • Status: Petition pending
  • Petition

U.S. Patent No. 9,732,149
Patent Owner: Alexion Pharmaceuticals Inc
Title: Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement

IPR2019-00741, filed by Amgen

  • Filing date: February 28, 2019
  • Status: Petition pending
  • Petition

Etanercept (Enbrel)+

U.S. Patent 8,163,522
Patent Owner:  Hoffman-Laroche
Title:  Human TNF receptor

IPR2017-01916, filed by Coherus

IPR2015-01792, filed by Coalition for Affordable Drugs

U.S. Patent 8,063,186
Patent Owner: Genentech
Title: Antibodies to PRO7436 polypeptides

IPR2017-02066, filed by Coherus

Insulin Glargine (Lantus)+

U.S. Patent No. 7,476,652
Patent Owner: Sanofi
Title: Acidic Insulin Preparations having Improved Stability

IPR2017-01526, filed by Mylan

U.S. Patent No. 7,713,930
Patent Owner: Sanofi

Title: Acidic insulin preparations having improved stability

IPR2017-01528, filed by Mylan

U.S. Patent No. 8,603,044
Patent Owner: Sanofi
Title: Pen-type injector

IPR2018-01675, filed by Mylan

IPR2018-01676, filed by Mylan

U.S. Patent No. 8,679,069
Patent Owner: Sanofi
Title: Pen-type injector

IPR2018-01670, filed by Mylan

IPR2019-00979, filed by Hospira, Pfizer

  • Filing date: May 2, 2019
  • Status: Petition pending.
  • Petition

U.S. Patent No. 8,992,486
Patent Owner: Sanofi
Title: Pen-type injector

IPR2018-01677 , filed by Mylan

  • Filing date: September 10, 2018
  • Status: Petitioner’s unopposed motion to dismiss granted.
  • Petition

IPR2018-01678, filed by Mylan

IPR2019-00122, filed by Mylan

IPR2018-01679, filed by Mylan

IPR2019-00980, filed by Hospira, Pfizer

  • Filing date: May 2, 2019
  • Status: Petition pending.
  • Petition

IPR2019-00981, filed by Hospira, Pfizer

  • Filing date: May 2, 2019
  • Status: Petition pending.
  • Petition

IPR2019-00982, filed by Hospira, Pfizer

  • Filing date: May 2, 2019
  • Status: Petition pending.
  • Petition

U.S. Patent No. 9,526,844
Patent Owner: Sanofi
Title: Pen-type injector

IPR2018-01680, filed by Mylan

IPR2018-01682, filed by Mylan

IPR2018-01696, filed by Mylan

IPR2019-01022, filed by Hospira, Pfizer

  • Filing date: May 2, 2019
  • Status: Petition pending.
  • Petition

IPR2019-01023, filed by Hospira, Pfizer

  • Filing date: May 2, 2019
  • Status: Petition pending.
  • Petititon

U.S. Patent No. 9,604,008
Patent Owner: Sanofi
Title: Pen-type injector

IPR2018-01684, filed by Mylan

IPR2019-00987, filed by Hospira, Pfizer

  • Filing date: May 2, 2019
  • Status: Petition pending.
  • Petition

Natalizumab (Tysabri)+

U.S. Patent 8,815,236
Patent Owner: Biogen
Title: Method for Treating Multiple Sclerosis and Crohn’s Disease

IPR2016-00912, filed by Swiss Pharma

U.S. Patent 8,349,321
Patent Owner: Biogen
Title:  Immunoglobin Formulation and Method of Preparation Thereof

IPR2016-00915, filed by Swiss Pharma

U.S. Patent 8,900,577
Patent Owner: Biogen
Title: Immunoglobulin Formulation and Method of Preparation thereof

IPR2016-00916, filed by Swiss Pharma

Pegfilgrastim (Neulasta)+

U.S. Patent 8,952,138
Patent Owner: Amgen
Title: Refolding proteins using a chemically controlled redox state

IPR2016-01542, filed by Apotex

U.S. Patent 9,856,287
Patent Owner: Amgen
Title: Refolding proteins using a chemically controlled redox state

PGR2019-00001, filed by Adello Biologics, LLC

Rituximab (Rituxan)+

U.S. Patent 7,820,161
Patent Owner: Biogen
Title: Treatment of Autoimmune Diseases

IPR2016-01614, filed by Celltrion

IPR2017-01115, filed by Pfizer

IPR2015-00415, filed by Boehringer Ingelheim

IPR2015-01744, filed by Celltrion

  • Filing date: August 17, 2015
  • Status: Terminated prior institution following motion to dismiss by petitioner on October 6, 2015.
  • Petition

U.S. Patent 7,976,838
Patent Owner: Genentech
Title: Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNFa inhibitor

IPR2016-01667, filed by Celltrion

IPR2017-02042, filed by Sandoz

IPR2017-02036, filed by Sandoz

IPR2017-01923, filed by Pfizer

IPR2015-00417, filed by Boehringer Ingelheim

IPR2015-01733, filed by Celltrion

  • Filing date: August 14, 2015
  • Status: Terminated prior to institution following motion to dismiss by petitioner on October 6, 2015.
  • Petition

IPR2018-01019, filed by Celltrion

  • Filing date: May 4, 2018
  • Status: Institution and Motion for joinder with IPR2017-01923 pending as of May 4, 2018.
  • Petition

U.S. Patent 8,329,172
Patent Owner:  Biogen
Title:  Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody

IPR2017-01093, filed by Celltrion

IPR2017-01166, filed by Pfizer

IPR2015-00418, filed by Boehringer Ingelheim

IPR2018-00285, filed by Pfizer

U.S. Patent 8,557,244
Patent Owner: Biogen
Title:  Treatment of Aggressive Non-Hodgkins Lymphoma with Anti-CD20 Antibody

IPR2017-01094, filed by Celltrion

IPR2017-01167, filed by Pfizer

U.S. Patent 9,296,821
Patent Owner: Biogen
Title: Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibodies

IPR2017-01095, filed by Celltrion

IPR2018-00186, filed by Pfizer

U.S. Patent 7,682,612
Patent Owner:  Genentech
Title:  Treatment of Hematologic Malignancies Associated with Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody

IPR2017-01227, filed by Celltrion

IPR2017-01230, filed by Celltrion

IPR2017-02126, filed by Pfizer

U.S. Patent 8,206,711
Patent Owner: Genentech
Title: Treatment of Chronic Lymphocytic Leukemia Using Anti-CD20 Antibodies

IPR2017-01229, filed by Celltrion

IPR2017-02127, filed by Pfizer

U.S. Patent 8,821,873
Patent Owner: Biogen
Title: Treatment of Diffuse Large-cell Lymphoma with Anti-CD20 Antibody

IPR2017-01168, filed by Pfizer

U.S. Patent 8,545,843
Patent Owner: Biogen
Title: Treatment of Vasculitis

IPR2018-00086, Petitioner: Pfizer

U.S. Patent 9,504,744
Patent Owner: Biogen
Title: Treatment of Diffuse Large-Cell Lymphoma with Anti-CD20 Antibody

IPR2018-00231, filed by Pfizer

Trastuzumab (Herceptin)+

U.S. Patent 6,407,213
Patent Owner: Genentech
Title: Methods for Making humanized antibodies

IPR2017-02139, filed by Samsung Bioepis

IPR2017-02140, filed by Samsung Bioepis

  • Filing date: September 29, 2017
  • Status: Final Written Decision finding claims 1, 2, 4, 12, 25, 29–31, 33, 42, 60, 62–64, 66, 67, 69, 71, 73, 74, 78, 80, and 81 are unpatentable and claims 65, 72, 75–77, and 79 are not unpatentable.
  • Petition
  • Institution Decision
  • Final Written Decision

IPR2017-02031, filed by Boehringer Ingelheim

IPR2017-02032, filed by Boehringer Ingelheim

IPR2017-01488, filed by Pfizer

IPR2017-01489, filed by Pfizer

IPR2017-01373, filed by Celltrion

  • Filing date: May 8, 2017
  • Status: Final Written Decision finding claims 1, 2, 4, 12, 25, 29–31, 33, 42, 60, 62–64, 66, 67, 69, 71, 73, 74, 78, 80, and 81 are unpatentable and claims 65, 72, 75–77, and 79 are not unpatentable.
  • Petition
  • Institution Decision
  • Final Written Decision

IPR2017-01374, filed by Celltrion

IPR2016-01693, filed by Mylan

IPR2016-01694, filed by Mylan

U.S. Patent 7,846,441
Patent Owner: Genentech
Title: Treatment with Anti-ErbB2 Antibodies

IPR2017-01121, filed by Celltrion

IPR2017-00731, filed by Pfizer

IPR2018-00016, filed by Pfizer

IPR2017-02063, filed by Pfizer

IPR2018-00192, filed by Samsung Bioepis

U.S. Patent 7,892,549
Patent Owner: Genentech
Title:  Treatment with Anti-ErbB2 Antibodies

IPR2017-01122, filed by Celltrion

IPR2017-00737, filed by Pfizer

IPR2017-00739, filed by Pfizer

IPR2017-01960, filed by Samsung Bioepis

U.S. Patent 6,627,196
Patent Owner: Genentech
Title: Dosages for Treatment with Anti-ErbB2 Antibodies

IPR2017-01139, filed by Celltrion

IPR2017-00804, filed by Pfizer

IPR2017-01958, filed by Samsung Bioepis

U.S. Patent 7,371,379
Patent Owner: Genentech
Title:  Dosages for Treatment with  Anti-ErbB2 Antibodies

IPR2017-01140, filed by Celltrion

IPR2017-00805, filed by Pfizer

IPR2017-01959, filed by Samsung Bioepis

U.S. Patent 8,591,897
Patent Owner: Genentech
Title:  Anti-ErbB2 Antibody Adjuvant Therapy

IPR2017-01726, filed by Pfizer

IPR2017-01727, filed by Pfizer

IPR2017-00959, filed by Celltrion

  • Filing date: February 21, 2017
  • Status: Terminated following Patent Owner request for adverse judgment on September 11, 2017.
  • Petition

U.S. Patent 6,339,142
Patent Owner: Genentech
Title: Protein Purification

IPR2017-02019, filed by Pfizer

IPR2018-00330, filed by Pfizer

U.S. Patent 9,249,218
Patent Owner:  Genentech
Title: Protein Purification

IPR2017-02020, filed by Pfizer

IPR2018-00331, filed by Pfizer

General Biologic Patents+

U.S. Patent 6,716,602
Patent Owner: Genentech
Title:  Metabolic Rate Shifts in Fermentations Expressing Recombinant Proteins

IPR2016-01608, filed by bioeq

U.S. Patent 9,051,556
Patent Owner: Shire
Title: Purification of iduronate-2-sulfatase

IPR2016-00258, filed by Green Cross Corp.

U.S. Patent 6,946,292
Patent Owner: Kyowa Kakko Kirin Co
Title:  Cells producing compositions with increased antibody dependent cytotoxic activity

IPR2017-01252, filed by Aragen Bioscience

U.S. Patent 8,067,232
Patent Owner: Kyowa Hakko Kirin Co.
Title: Antibody composition-producing cell with inactivated A-1, 6-fusocyltransferase

IPR2017-01254, filed by Aragen Bioscience

U.S. Patent 7,425,446
Patent Owner: Kyowa Hakko Kirin Co.
Title: Antibody composition-producing cell

IPR2017-01262, filed by Aragen Bioscience

U.S. Patent 7,332,289
Patent Owner: Chugai Pharmaceutical Co.
Title: Method of Purifying Protein

IPR2017-01357, filed by Pfizer

U.S. Patent 7,927,815
Patent Owner: Chugai Pharmaceutical Co.
Title: Protein Purification Method

IPR2017-01358, filed by Pfizer

U.S. Patent 6,870,034
Patent Owner: Genentech
Title:  Protein Purification

IPR2017-02029, filed by Boehringer Ingelheim

U.S. Patent 6,331,415
Patent Owner: Genentech
Title: Methods of producing immunoglobulins, vectors and transformed host cells for use therein

IPR2016-01373, filed by Merck Sharp & Dohme Corp.

IPR2016-00710, filed by Mylan

IPR2017-00047, filed by Merck Sharp & Dohme Corp.

IPR2016-00383, filed by Genyzme Corp.

IPR2015-01624, filed by Sanofi-Aventis

IPR2016-00460, filed by Genzyme

U.S. Patent 7,807,799
Patent Owner:  Genentech
Title:  Reducing protein A leaching Affinity Chromatography

IPR2016-01837, filed by Pfizer

U.S. Patent 8,940,878
Patent Owner: Amgen
Title: Capture purification processes for proteins expressed in a non-mammalian system

IPR2019-00791, filed by Kashiv Biosciences, LLC

  • Filing date: March 7, 2019
  • Status: Petition pending.
  • Petition

U.S. Patent 9,643,997
Patent Owner: Amgen
Title: Capture purification processes for proteins expressed in a non-mammalian system

IPR2019-00797, filed by Kashiv Biosciences, LLC

  • Filing date: March 7, 2019
  • Status: Petition pending.
  • Petition

IPR2019-01183, filed by Fresenius Kabi USA, LLC and Fresenius Kabi Swissbiosim GmbH

  • Filing date: June 8, 2019
  • Status: Petition pending.
  • Petition

This page is maintained by Lindsey Wanner.